The quarter cleared the market’s bar on both profit and sales. Non-GAAP EPS was $3.02, above the published consensus of $2.74 by $0.28, while revenue of $1.004 billion exceeded the published estimate of roughly $976 million. That is a meaningful beat, particularly because reported sales still fell year over year after the business divestitures. (Schedule 1; Schedule 5)
| Metric | Q2 2026 actual | Q2 2025 / expectation | Read-through |
|---|---|---|---|
| Revenue | $1.004B | $1.032B prior year; ~$976M consensus | Above expectations despite a 2.7% reported decline (Schedule 1) |
| Organic revenue growth | 0.1% | (0.7)% in H1; annual prior outlook: (1.5)% to (0.5)% | Returned to essentially flat growth as divestiture and FX effects masked the underlying result (Schedule 6; 2026 Guidance) |
| Non-GAAP diluted EPS | $3.02 | $3.12 prior year; $2.74 consensus | $0.28 beat, though down 3.2% year over year (Schedule 5) |
| Non-GAAP operating margin | 20.5% | 22.1% prior year | Core profitability still compressed 160 bps (Schedule 4) |
| FY 2026 non-GAAP EPS guide | $11.15–$11.45 | Prior: $10.80–$11.30; published consensus: ~$11.12 | Midpoint rose $0.25 and sits above consensus (2026 Guidance) |
| FY 2026 organic revenue guide | 0.0%–1.0% | Prior: (1.5)%–(0.5)% | A material shift from an expected decline to modest growth (2026 Guidance) |
The guidance change is more important than the headline beat. Management lifted full-year organic-growth guidance by roughly 1.5 percentage points at the midpoint, from a decline to 0%–1% growth, and raised adjusted EPS guidance by $0.25 at the midpoint. The revised revenue outlook of roughly $3.88–$3.92 billion also exceeds the standing published expectation of about $3.85 billion. This resets the near-term narrative from contraction to stabilization with modest growth. (2026 Guidance)
Demand improved, but not evenly enough to call the recovery broad-based yet. Discovery and Safety Assessment—by far the largest segment—grew organic revenue just 0.2%, while Manufacturing grew 1.3% organically. Research Models and Services remained the weak point, down 1.4% organically. The improved DSA booking trend supports the upgraded outlook, but the reported quarter itself shows only a very early recovery in underlying sales. (Schedule 4; Schedule 6)
The quality caveat is margins, not the GAAP loss. Adjusted operating margin fell to 20.5% from 22.1%, with higher DSA study costs and corporate costs offsetting the better demand picture. Moreover, the quarter’s EPS included a $0.19-per-share benefit from investment gains in the deferred-compensation plan; management says that benefit should be largely offset by a higher tax rate across the full year. So the earnings beat is real, but not all of it reflects a structural margin improvement. (Schedule 4; Schedule 5)
The GAAP loss is principally transaction accounting rather than a new operating setback. The company reported a $0.03 GAAP loss per share, largely because the CDMO and Cell Solutions divestitures produced a $63.7 million quarterly loss. Those charges also drive the sharp reduction in GAAP EPS guidance to $3.05–$3.35, even as adjusted guidance rises. Investors focused on the continuing business should separate that divestiture accounting from the modestly improved operating outlook. (Schedule 1; Schedule 5; 2026 Guidance)
Read the original 8-K on SEC EDGAR ↗